| Date | Title | Description |
| 17.09.2024 | FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer | Ad hoc announcement pursuant to Art. 53 LR
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2
Kisqali® (ribo... |
| 12.09.2024 | NCCN Commits to Sharing Award-Winning Resources for People with Cancer in Spanish and Other Languages | Translations are underway for the entire library of NCCN Guidelines for Patients to empower people with cancer and caregivers worldwide to make informed treatment decisions that are best for them.
PLYMOUTH MEETING, Pa., Sept. 12, 2024 /PRNe... |
| 11.09.2024 | Building Bridges in Cancer Care: The Push for Diversity and Inclusion | In the heart of Washington, D.C., a significant conversation unfolded at the National Comprehensive Cancer Network (NCCN) Policy Summit. The focus? Diversity, equity, and inclusion (DEI) in oncology. This summit was not just another meeting... |
| 10.09.2024 | NCCN Policy Summit Explores how to Build an Inclusive Cancer Center Workplace Culture that Better Serves Everybody | Speakers at the National Comprehensive Cancer Network's event discussed the importance of diversity, equity, and inclusion (DEI) as integral to the oncology workforce to improve cancer outcomes, and what to do about backlash.
WASHINGTON, Se... |
| 10.09.2024 | Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) | Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management
SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- J... |
| 05.09.2024 | New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal Cancers | Researchers found that omitting the bolus-specific 5-flourouracil (5-FU) portion from common chemotherapy regimens could improve tolerability for patients without sacrificing treatment effectiveness.
PLYMOUTH MEETING, Pa., Sept. 5, 2024 /PR... |
| 30.07.2024 | Bridging Borders: NCCN's Commitment to Global Cancer Care | In the realm of healthcare, collaboration is the lifeblood of progress. The National Comprehensive Cancer Network (NCCN) exemplifies this principle through its recent initiatives aimed at enhancing cancer care worldwide. Two significant dev... |
| 30.07.2024 | NCCN and Medlive Renew Collaboration to Enhance Cancer Care in China | United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncology guidelines in China
PLYMOUTH MEETING, Pa., July 30, 2024 /PRNewswire/ -- The Nati... |
| 24.07.2024 | NCCN Oncology Research Program Celebrates 25 Years of Advancing Cancer Science | The National Comprehensive Cancer Network (NCCN)'s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
PLYMOUTH MEETING, Pa., Ju... |
| 08.07.2024 | Olverembatinib Approved for Commercialization in Macau China | ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological m... |
| 04.07.2024 | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of a... |
| 26.06.2024 | New Survey from NCCN Finds Cancer Drug Shortage Management Remains a Moving Target, Impacting Clinical Trials | Specific carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.
PLYMOUTH MEET... |
| 17.06.2024 | Multiple New Awards Recognize NCCN as Exceptional Source for Information for Cancer Patients and Caregivers | NCCN Guidelines for Patients earn Hermes Award for electronic media and Communicator Award for medical print content.
NCCN Patient Webinars earns Digital Health Award and Viddy Award for outstanding achievement in video and digital producti... |
| 21.05.2024 | Dignitana signs an exclusivity agreement for Japan with Konica Minolta | Dignitana signs an exclusivity agreement for Japan with Konica Minolta
Tue, May 21, 2024 10:03 CET Report this content
Dignitana has signed a new multi-year Distribution Agreement for technology market leader Konica Minolta to be the exclus... |
| 21.05.2024 | Oncology Events in Poland Solidify Collaboration with NCCN | The National Comprehensive Cancer Network participates in meetings hosted by Maria Sklodowska-Curie National Research Institute of Oncology, the Polish Oncological Society, and Alliance for Innovation to advance work adapting proven cancer ... |
| 16.05.2024 | Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN--Journal of the National Comprehensive Cancer Network | Chief of the Genitourinary Division for Fox Chase Cancer Center, and Member of two NCCN Guidelines Panels to oversee high-impact oncology research journal.
PLYMOUTH MEETING, Pa., May 16, 2024 /PRNewswire/ -- Daniel M. Geynisman, MD, is bein... |
| 29.04.2024 | Truqap recommended for EU breast cancer approval | Truqap recommended for EU breast cancer approval
Mon, Apr 29, 2024 08:05 CET Report this content
29 April 2024
Truqap plusFaslodex recommended for approval in the EU by CHMP for
patients with advanced ER-positive breast cancer
Recommendatio... |
| 17.04.2024 | National Comprehensive Cancer Network Awards Champions for Excellence and Outstanding Contributions in Cancer Care | Dr. Shaji Kumar, Darcie Green, and members of the NCCN Covid-19 Vaccine Advisory Committee honored for their contributions to improving cancer care over the years; Donna Black named NCCN Employee of the Year.
PLYMOUTH MEETING, Pa., April 17... |
| 08.04.2024 | Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network | Dr. Christopher Lieu of the University of Colorado elected as incoming Vice-Chair for the alliance of leading cancer centers.
PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofi... |
| 01.04.2024 | Health | Overdosing on chemo: A common gene test could save hundreds of lives each year | Arthur Allen | KFF Health News (TNS)
One January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died in excruciating pain from the very drug meant to prolong her life.
Ro... |
| 25.03.2024 | Dignitana nominated for inaugural Texas Impact Enterprise Awards | Dignitana nominated for inaugural Texas Impact Enterprise Awards
Mon, Mar 25, 2024 15:02 CET Report this content
Dignitana announces that it has been nominated for the inaugural Texas Impact Enterprise Awards. The award recognizes organizat... |
| 25.03.2024 | Health | Breast cancer test may make bad chemotherapy recommendations for Black patients, UIC study shows | While the rest of the world was in the throes of the pandemic, Valletta Howard was wrapping her mind around a breast cancer diagnosis.
After finding a lump in her left breast in April 2021, she confirmed it with a mammogram and ultrasound i... |
| 22.03.2024 | The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine | SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metast... |
| 19.03.2024 | Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study | The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy;
The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse ... |
| 07.03.2024 | Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao | Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer
HONG KONG and MACAO, March 7, 2024 /PRNewswire/ -- A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong C... |
| 07.03.2024 | DigniCap Delta study underway in Brindisi, Italy | DigniCap Delta study underway in Brindisi, Italy
Thu, Mar 07, 2024 08:10 CET Report this content
Dignitana announces that Antonio Perrino Hospital in Brindisi, Italy has initiated a clinical study of the DigniCap Delta Scalp Cooling System ... |
| 29.02.2024 | Dignitana to exhibit at Onkologidagarna in Malmö | Dignitana to exhibit at Onkologidagarna in Malmö
Thu, Feb 29, 2024 10:39 CET Report this content
Dignitana AB, scalp cooling innovation leader, will present the advanced technology of the DigniCap Delta Scalp Cooling System at Onkologidaga... |
| 12.02.2024 | DigniCap Delta receives market approval in Japan | DigniCap Delta receives market approval in Japan
Mon, Feb 12, 2024 09:02 CET Report this content
Dignitana announces that DigniCap Delta received market approval in Japan from the Ministry of Health, Labor and Welfare (MHLW). In Japan, Dign... |
| 02.02.2024 | Dignitana convenes Training Academy bringing distributors to Lund Headquarters | Dignitana convenes Training Academy bringing distributors to Lund Headquarters
Fri, Feb 02, 2024 10:00 CET Report this content
Scalp cooling innovator Dignitana AB has brought together MedTech experts from five regions around the globe for ... |
| 17.01.2024 | Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) | SUZHOU, China, and ROCKVILLE, Md., Jan. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 16.01.2024 | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy
Tue, Jan 16, 2024 10:14 CET Report this content
Dignitana announces that the Hospital de Clínicas in Montevideo, Uruguay has completed the first stage of a two-year... |
| 15.01.2024 | Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein | Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein
Mon, Jan 15, 2024 13:00 CET Report this content
Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp... |
| 08.12.2023 | Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions | With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall surviva... |
| 17.11.2023 | Truqap approved in US for HR+ breast cancer | Truqap approved in US for HR+ breast cancer
Fri, Nov 17, 2023 08:00 CET Report this content
17 November 2023
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
First-in-class AKT inhi... |
| 13.11.2023 | The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option | The news that the U.K. has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a patient in her breast cancer prevention cli... |
| 26.10.2023 | What are the 4 Pillars of Cancer Care? | Cancer remains the second most common cause of mortality in the U.S., and according to recently published data from 17 National Cancer Institute registries, younger adults are increasingly diagnosed with common cancers. Specifically, cancer... |
| 05.10.2023 | Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’ | The shortage of cancer drugs is not going away, but it may be easing slightly, a new national survey suggests. Based on questions posed to 29 of its 33 member hospitals, the National Comprehensive Cancer Network said Thursday that 86% of th... |
| 04.10.2023 | Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States | Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States
Wed, Oct 04, 2023 08:45 CET Report this content
Scalp cooling innovator Dignitana AB announces today a sales and mar... |
| 06.09.2023 | Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer | The first and only anti-PD-1 antibody approved for treating cervical cancer in China
ORR of 27.8%, mPFS of 3.7m, and mOS of 16.8m achieved as monotherapy with best-in-class potential
A Phase 3 trial (VICT-004) of zimberelimab in combination... |
| 17.08.2023 | Medicare beneficiaries deserve access to genetic counselors | Precision medicine driven by genetic health care is knocking on the door. It offers hope that, sooner than later, we can address health problems like Alzheimer’s disease, cancer, and heart disease that affect the lives of so many Americans.... |
| 16.08.2023 | Why drug shortages are having an outsize impact on ovarian cancer patients | Sarah Evans considers herself a lucky ovarian cancer patient, though she is dealing with the second recurrence of the disease since she was first diagnosed in February 2018.
She is grateful that, even by her third round of chemo in March of... |
| 27.07.2023 | Clinical pathways are the currency of health tech | Jeff Diamond Contributor
Share on Twitter
Jeff Diamond is a senior associate at Fika Ventures.
Aaron Szekel Contributor
Aaron Szekel is a venture partner at Fika Ventures.
As healthcare becomes more entrenched in the digital revolution, the... |
| 10.07.2023 | Worsening Cancer Drug Shortages Are A Public Health Emergency | FILE - In this photo, chemotherapy drugs are administered to a patient at a hospital in Chapel Hill, ... [+] N.C. A growing shortage of common cancer treatments is forcing doctors to switch medications and delaying care, prominent U.S. canc... |
| 15.06.2023 | FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer | SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- Biostar Pharma, Inc. (hereinafter referred to as "Biostar"), the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusin... |
| 22.03.2023 | Dignitana enters Hong Kong market with leading distributor Science International Corporation | Dignitana enters Hong Kong market with leading distributor Science International Corporation
Wed, Mar 22, 2023 08:20 CET Report this content
Scalp cooling innovator Dignitana AB has signed Science International Corporation, a leading distri... |
| 23.02.2023 | More physicians are calling for fallopian tube removal to prevent ovarian cancer | Ovarian cancer has long been one of the deadliest cancers to strike women.
No tests are available to detect it early, so most patients are diagnosed in later stages, when the cancer is more likely to have spread. Fewer than half of women su... |
| 04.02.2023 | Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day | An ongoing pilot project aims to evaluate the feasibility of implementing the Health Equity Report Card as a tool for improving the quality and equity of cancer care and continues the Elevating Cancer Equity collaboration from the National ... |
| 15.12.2022 | International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers | ACC, NCCN, ACS, and CHAI collaborate to launch new NCCN Harmonized Guidelines for Sub-Saharan Africa focused on pediatric cancers; available free at NCCN.org/harmonized.
DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNe... |
| 13.12.2022 | Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors | Researchers from City of Hope find only 30% of people with neuroendocrine tumors consider living longer to be their single top priority; 70% said addressing and overcoming pain, fatigue, or lack-of-function was more important than just prol... |
| 08.12.2022 | Capivasertib PFS in HR-positive breast cancer | Capivasertib PFS in HR-positive breast cancer
Thu, Dec 08, 2022 14:30 CET Report this content
8 December 2022 13:30 GMT
Capivasertib plus Faslodex reduced the risk of disease progression or
death by 40% versus Faslodex in advanced HR-positi... |
| 02.12.2022 | Improving Cancer Outcomes for LGBTQ+ Patients Requires Earning Trust and Challenging Assumptions | Annual NCCN Patient Advocacy Summit explores stories and data highlighting barriers to high-quality care that LGBTQ+ people with cancer experience, examining persistent setbacks and promising developments.
PLYMOUTH MEETING, Pa., Dec. 2, 202... |
| 16.11.2022 | SLACOM and NCCN Launch International Project to Improve Breast Cancer Care in Argentina | National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast cancer care, starting in Argentina and then ... |
| 02.11.2022 | NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide | United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at ... |
| 19.10.2022 | NCCN Guidelines for Patients Win Award for Excellence in Cancer Patient Education from CPEN | National Comprehensive Cancer Network's breast cancer patient resources honored for unique support of diversity, equity, and inclusion, available free at NCCN.org/patientresources.
PLYMOUTH MEETING, Pa., Oct. 19, 2022 /PRNewswire/ -- The Na... |
| 10.10.2022 | On World Mental Health Day, NCCN Announces Free Updated Distress Screening Tool, Available in More Than 70 Languages | The National Comprehensive Cancer Network's Distress Thermometer helps people with cancer worldwide receive better care by empowering discussion and recommending best practices for managing psychological wellness.
PLYMOUTH MEETING, Pa., Oct... |
| 16.09.2022 | Cancer Screening Gaps Highlight Urgent Need to Address Health Inequities, According to NCCN Policy Summit | National Comprehensive Cancer Network's #NCCNPolicy Summit, featuring White House Moonshot Coordinator and representatives from CDC, NCI, and USPSTF, examines critical need for improvements in cancer prevention and early detection across th... |
| 13.09.2022 | NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer | An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type
PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer N... |
| 12.09.2022 | In a nod to JFK, Biden pushes "moonshot" to fight cancer | President Biden channeled John F. Kennedy on the 60th anniversary of JFK's moonshot speech on Monday, highlighting Biden administration efforts aimed at "ending cancer as we know it."
The president traveled to Boston on Monday to ... |
| 09.09.2022 | New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients | According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy ... |
| 27.07.2022 | BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging | Telix and BAMF Health use Illuccix® (kit for the preparation of Gallium Ga 68 gozetotide injection) for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging
GRAND RAPIDS, Mich. and INDIANAPOLIS, July 27, 2022 /P... |
| 27.07.2022 | NCCN Publishes New Patient Guidelines for Breast Cancer Screening and Diagnosis Emphasizing Annual Mammograms for All Average-Risk Women Over 40 | The free evidence-based, expert consensus resource, available at NCCN.org/patientguidelines, helps people ask the right questions about when and how often to screen.
PLYMOUTH MEETING, Pa., July 27, 2022 /PRNewswire/ -- The National Comprehe... |
| 12.07.2022 | National Comprehensive Cancer Network Shares New Recommendations for Treating Children with Brain Tumors | Newly-published NCCN Guidelines for Pediatric Central Nervous System Cancers synthesize latest evidence to help care teams ensure children with high-grade gliomas have best possible outcomes; available free at NCCN.org.
PLYMOUTH MEETING, Pa... |
| 21.06.2022 | JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation | New population study on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
PLYMOUTH ME... |
| 01.06.2022 | The Access to Rare Indications Act could be a game changer for millions of Americans | The term “medically necessary” is the yardstick by which insurance companies, including Medicare and Medicaid, decide if they will pay for a particular treatment. For the millions of Americans living with rare diseases, most of which do not... |
| 22.04.2022 | Telix Further Strengthens European Distribution Network for Illuccix | MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertrie... |
| 14.04.2022 | First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent | Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent
Typically diagnosed in men over 50, prostate cancer is the second leading... |
| 31.03.2022 | NCCN Annual Conference Focuses on Cancer Patient Journey; with Cutting-Edge Research and Latest Evidence-Based Care Recommendations | Three-day #NCCN2022 virtual oncology conference from National Comprehensive Cancer Network includes didactic presentations, interactive discussions, and challenging case reviews.
PLYMOUTH MEETING, Pa., March 31, 2022 /PRNewswire/ -- The NCC... |
| 28.03.2022 | Free Guide to Colorectal Cancer Screening from NCCN Now Available in More Than a Dozen Languages | NCCN Guidelines for Patients: Colorectal Cancer Screening now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer.
PLYMOUTH MEETING, Pa.March 28, 2022 /PRNewswire/ -- The ... |
| 09.03.2022 | NCCN Expands Resources for Treating Rare Cancer Types | The National Comprehensive Cancer Network publishes two new NCCN Guidelines for Malignant Peritoneal Mesothelioma and for Ampullary Adenocarcinoma, to standardize treatment and improve outcomes for these rare tumor types; also reaches miles... |
| 08.02.2022 | mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN | Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no diff... |
| 04.02.2022 | NCCN Joins the Call to 'Close the Care Gap' on World Cancer Day | Global nonprofit National Comprehensive Cancer Network participates in annual awareness day, highlighting cancer care disparities and free resources to help, detailed at NCCN.org/wcd.
PLYMOUTH MEETING, Pa., Feb. 4, 2022 /PRNewswire/ -- Worl... |
| 24.01.2022 | NCCN Announces Funding for Lung and Thyroid Cancer Quality Projects, in Collaboration with Lilly | PLYMOUTH MEETING, Pa., Jan. 24, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new funding for quality projects to improve patient care and outcomes in lung and thyroi... |
| 10.01.2022 | New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation | PLYMOUTH MEETING, Pa., Jan. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occur... |
| 23.12.2021 | Global Recommendations for Colon Cancer Translated into Multiple Languages as NCCN Expands Arabic Resources | New Arabic-language resources for health care providers, caregivers, and people with cancer, help set cancer care standards worldwide based on the latest evidence and expert-consensus.
PLYMOUTH MEETING, Pa., Dec. 23, 2021 /PRNewswire/ -- Th... |
| 20.12.2021 | Cardinal Health : to distribute Telix's newly FDA-approved prostate cancer radiopharmaceutical | Cardinal Health to distribute Telix's newly FDA-approved prostate cancer radiopharmaceutical
12/20/2021
FDA Approves Telix's Prostate Cancer Imaging Product, Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) - 20 December 2021. ... |
| 14.12.2021 | New NCCN Guidelines help Patients Better Understand and Participate in the Care of their Cervical Cancer | The free resource, available at NCCN.org/patientguidelines, helps patients know what to expect and participate actively in decisions about their care.
PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ -- The National Comprehensive Cancer Ne... |
| 07.12.2021 | Updated NCCN Distress Thermometer and Problem List Helps People Cope with Cancer Symptoms and Treatment | Landmark tool for measuring the psycho-social impact of cancer gets an overhaul to reflect the latest research, helping patients receive better care by addressing their physical and emotional wellbeing.
PLYMOUTH MEETING, Pa., Dec. 7, 2021 /... |
| 01.12.2021 | When and How to Screen for Colorectal Cancer? New NCCN Patient Guideline Explains Latest Timing and Approaches | PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Colorectal Cancer Screening. Colorectal cancer (CRC) is the fourth m... |
| 16.11.2021 | New Study in JNCCN Finds Disturbing Lack of Key Leukemia Medication | PLYMOUTH MEETING, Pa., Nov. 16, 2021 /PRNewswire/ -- New research in the November 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood... |
| 25.10.2021 | NCCN Works with Polish Health Leaders to Improve Cancer Standardization, Coordination, and Outcomes | PLYMOUTH MEETING, Pa., Oct. 25, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—today announced the publication of new NCCN Guidelines® for Cervical Cancer: ... |
| 22.10.2021 | Roche : VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab) | Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1
The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit... |
| 22.10.2021 | Press Release : Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq(R) (atezolizumab) | -- Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 -- The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may b... |
| 13.10.2021 | New Information from NCCN on Most Common Type of Cancer; Diagnosed in Millions Every Year | New NCCN Guidelines for Patients: Basal Cell Skin Cancer empowers patients and caregivers with knowledge about this widespread, preventable, and easily-cured cancer plus the rare subset that requires more aggressive treatment.
PLYMOUTH MEET... |
| 04.10.2021 | NCCN Meeting on Blood Cancers Empowers Interprofessional Care Teams | The NCCN 2021 Virtual Congress: Hematologic Malignancies ( #NCCNhem21 ) will provide the latest evidence and expert consensus on emerging practices and issues in blood cancer treatment, online October 14-16, 2021.
PLYMOUTH MEETING, Pa., Oct... |
| 30.09.2021 | NCCN Publishes New Guide to Improving Knowledge and Quality of Life for Small Cell Lung Cancer Patients | New patient and caregiver resource from the National Comprehensive Cancer Network provides free expert consensus information on improving outcomes for people with an aggressive type of lung cancer.
PLYMOUTH MEETING, Pa., Sept. 30, 2021 /PRN... |
| 21.09.2021 | How Inheret drives early detection for genetic cancers with its guidelines-based tool | Inheret CEO and Founder Dr. David F. Keren talks about the origins of the cancer risk detection platform and his mission to identify hereditary diseases early.
Why did you start this company?
We started Inheret because it’s something that w... |
| 13.09.2021 | HUTCHMED China : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma (Form 6-K) | HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
Hong Kong, Shanghai & Florham Park, NJ - Monday, September 13, 2021: HUTCHMED (China) Lim... |
| 13.09.2021 | HUTCHMED China : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma | HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Produ... |
| 08.09.2021 | NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese
USA - English Россия - Pусский Deutschland - Deutsch Polska - Polski Slovensko - slovenčina Česko - čeština Fra... | |
| 08.09.2021 | NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese | PLYMOUTH MEETING, Pa., Sept. 8, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers in the United States—announces recently-updated versions of evidence- and expert consensu... |
| 27.08.2021 | JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions | Population–based cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs.
PLYMOUTH MEETING, Pa., Aug. 27, 2021 /PRNewswire/ -- Among all patients with n... |
| 26.08.2021 | JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions
USA - English USA - English | |
| 19.08.2021 | Mercy Medical Center Utilizes Single-Dose Breast Cancer Radiotherapy for Older Americans | IORT - Intraoperative Radiation Therapy "Unlike traditional whole breast radiation which may impact surrounding tissues, IORT only impacts the tumor bed. This makes IORT an especially appropriate treatment for older patients who may ne... |
| 09.08.2021 | Epizyme : and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK (tazemetostat) in Greater China | CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. - Epizyme, Inc. ('Epizyme') (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HU... |
| 29.07.2021 | Dignitana signs distributor B&Co Group to support Benelux Growth | Dignitana signs distributor B&Co Group to support Benelux Growth Thu, Jul 29, 2021 15:21 CET
Dignitana, world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region. ... |
| 15.07.2021 | NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc. | |
| 21.06.2021 | New Patient Guide from NCCN Jumpstarts Important Conversations About Anal Cancer | |
| 21.06.2021 | New Patient Guide from NCCN Jumpstarts Important Conversations About Anal Cancer | New and updated patient and caregiver resources from National Comprehensive Cancer Network offer jargon-free, state-of-the-art information on diagnosis, treatment, and surveillance for anal, colon, and rectal cancers.
PLYMOUTH MEETING, Pa.,... |
| 03.05.2021 | NCCN Releases New Patient Guidelines on Anemia and Neutropenia | New resource helps patients and caregivers recognize and understand blood cell production deficiencies, to better participate in their care planning; available for free at NCCN.org/patientguidelines
PLYMOUTH MEETING, Pa., May 3, 2021 /PRNew... |
| 22.04.2021 | BIOCARTIS GROUP NV
Press release Biocartis Group NV: Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ | PRESS RELEASE: REGULATED-INSIDE INFORMATION
22 April 2021, 07:00 CEST
Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™
Mechelen, Belgium, 22 April 20... |
